Navigation Links
4th International Nanomedicine Conference
Date:6/24/2013

The Australian Centre for Nanomedicine (ACN) at UNSW is hosting the fourth International Nanomedicine Conference from 1 3 July in Sydney.

The conference will bring together world-leading experts to highlight research into new drugs, targeted drug delivery systems, diagnostics and imaging, and regenerative medicine.

The ACN is an interdisciplinary research centre comprising UNSW scientists, engineers and clinicians who are working together to develop new treatments that could deliver a mighty blow in the fight against currently incurable diseases, including a range of chemo-resistant cancers.

Nanomedicine involves the development of new treatment and detection strategies in medicine that arise from nanotechnology, such as the synthesis of nano-sized particles that have been engineered to perform a very specific function inside the body.

One nanometre is equivalent to one-billionth of a metre and is roughly 60,000 times thinner than a human hair. A single strand of DNA is just three nanometres wide.

At this sub-microscopic scale, materials sometimes exhibit curious physical, chemical and biological properties. These can be exploited to create particles that release drugs in a highly controlled way or to develop sensors that can provide early detection of disease.

Keynote speakers include:

  • Heather Maynard, Director of the Chemistry Biology Interface Training Program at UCLA
  • John Mattick, Director of the Garvan Institute of Medical Research in Sydney
  • Scott McNeil, Director of the Nanotechnology Characterization Lab in Maryland, US

Things to watch from the Australian Centre for Nanomedicine at UNSW:

Researchers have begun work on a new drug that will target chemo-resistant pancreatic cancer. The objective is to break down and halt the spread of the cancer cells, and to simultaneously "switch off" genes associated with its development. Professor Maria Kavallaris, Co-Director of the Centre, says there are certainly "future applications across a range of cancers".

  • Phoebe Phillips from UNSW Medicine will speak about this work

UNSW researchers have teamed up with Sydney-based biotech company Benitec Biopharma to develop a "gene silencing" technology that has been shown in preclinical models to dramatically improve the effectiveness of chemotherapy in lung cancer.

  • Michael Graham, Chief Scientist at Benitec Biopharma, will speak about this work and how the company's unique gene silencing approach can target other diseases such as hepatitis C.

Event Details:

What: 4th Annual International Nanomedicine Conference
Where: Intercontinental Hotel, 117 Macquarie Street, Sydney CBD
When: 1-3 July 2013
Register online and see the full list of speakers at: http://www.oznanomed.org/


'/>"/>

Contact: Myles Gough
myles.gough@unsw.edu.au
61-407-061-209
University of New South Wales
Source:Eurekalert

Related biology news :

1. PETA International Science Consortium disappointed in denial of Dow appeal
2. First international collaboration to showcase latest body of evidence of dairy health benefits
3. SPIE on global team proposing International Year of Light at United Nations
4. CLEO: 2013 -- the Premier International Laser and Electro-Optics Event in San Jose next week
5. New review sets international standards for best practice in fracture liaison services
6. BGI hosts its 2nd International Conference on Genomics in the Americas
7. Drive-Up Biometric System from SRI International Sarnoff Wins New Product Showcase Award at ISC West 2013
8. International conference will put agri-food supply chain under the microscope
9. International collaboration to investigate disappearing reptiles and amphibians
10. International conference to tackle climate-change threats to agriculture
11. International study: Excess dietary salt may drive the development of autoimmune diseases
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/13/2016)... , April 13, 2016  IMPOWER physicians supporting ... are setting a new clinical standard in telehealth thanks ... By leveraging the higi platform, IMPOWER patients can routinely ... pulse and body mass index, and, when they opt ... and convenient visit to a local retail location at ...
(Date:3/29/2016)... 2016 LegacyXChange, Inc. (OTC: ... SelectaDNA/CSI Protect are pleased to announce our successful effort ... variety of writing instruments, ensuring athletes signatures against counterfeiting ... from athletes on LegacyXChange will be assured of ongoing ... Bill Bollander , CEO states, "By ...
(Date:3/22/2016)... and SANDY, Utah , March ... operates the highest sample volume laboratory in ... and UNIConnect, leaders in clinical sequencing informatics and molecular ... of a project to establish the informatics infrastructure for ... NSO has been contracted by the Ontario Ministry ...
Breaking Biology News(10 mins):
(Date:6/23/2016)... , ... June 23, 2016 , ... ... release of its second eBook, “Clinical Trials Patient Recruitment and Retention Tips.” Partnering ... retention in this eBook by providing practical tips, tools, and strategies for clinical ...
(Date:6/23/2016)... June 23, 2016 /PRNewswire/ - FACIT has announced ... biotechnology company, Propellon Therapeutics Inc. ("Propellon" ... commercialization of a portfolio of first-in-class WDR5 inhibitors ... such as WDR5 represent an exciting class of ... precision medicine for cancer patients. Substantial advances have ...
(Date:6/23/2016)... , ... June 23, 2016 , ... ... YM (Yeast and Mold) microbial test has received AOAC Research Institute approval 061601. ... microbial tests introduced last year,” stated Bob Salter, Vice President of Regulatory and ...
(Date:6/23/2016)... 23, 2016   EpiBiome , a precision microbiome ... in debt financing from Silicon Valley Bank (SVB). The ... to advance its drug development efforts, as well as ... "SVB has been an incredible strategic partner to ... traditional bank would provide," said Dr. Aeron Tynes ...
Breaking Biology Technology: